Primary Research · 2006
Efficacy of orally administered alpha-lipoic acid for symptomatic diabetic polyneuropathy: the SYDNEY 2 trial
Ziegler D, Ametov A, Barinov A, et al. · Diabetes Care, 2006
Key finding
5-week RCT (n=181) found oral ALA 600mg/day improved neuropathic symptom scores, with higher doses providing no additional benefit — supporting 600mg as the effective oral dose.
About the supplement
Alpha-Lipoic Acid (ALA)
Dose · mechanism · evidence grade · safety →
Read the paper
Open on PubMedhttps://pubmed.ncbi.nlm.nih.gov/17065669/
About this page
Formulate maintains a registry of clinical studies cited across its guides and evidence grades. This page links the study metadata to the content that cites it — one canonical entry per landmark study.
The full citation chain is public so readers can verify claims without hunting through individual guide pages. Browse all cited studies →
Note: Study summaries on this page are editorial interpretations of the research. Always consult the primary source before drawing clinical conclusions.